RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024
RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024
redhill biopharma終止Aemcolo的授權協議，用於治療旅行者腹瀉，將於2024年10月8日正式終止。
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual decision with Cosmo Technologies Ltd. ("Cosmo") to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea (the "License Agreement"). The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024.
RedHill生物製藥有限公司（納斯達克：RDHL）（“RedHill” 或 “本公司”），一家專業的生物製藥公司，今日宣佈與Cosmo Technologies Ltd.（“Cosmo”）共同決定自願終止他們的Aemcolo獨佔性美國許可協議，該協議是治療旅行者腹瀉的協議（“許可協議”）。 最初於2019年10月17日簽訂的許可協議將於2024年10月8日正式終止。